Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ASCEND GO-2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy

NCT03938545 is registered in ClinicalTrials.gov with Immunovant Sciences GmbH as lead sponsor.

NCT NCT03938545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03938545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ASCEND GO-2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy
Lead sponsor
Immunovant Sciences GmbH
Phase
Phase 2
Overall status
Terminated
Start date
July 23, 2019
Completion date
April 15, 2021
Enrollment
65 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

graves' ophthalmopathy (go)